Table 4.
Relative systemic exposure and absolute bioavailability of BDP, B-17-MP and calculated total BOH following administration of BDP intravenously and via the oral, intranasal and inhaled routes with and without activated charcoal.
| AUC normalized to a 1000 µg dose | Bioavailability relative to intravenous2 | ||||||
|---|---|---|---|---|---|---|---|
| Route | Analyte1 | No charcoal AUC (pg ml−1 h) | With charcoal AUC (pg ml−1 h) | Total (%F) | Oral (%F) | Lung (%F) | Nose (%F) |
| Intravenous | BDP | 6660 | – | 100 | – | – | – |
| Inhaled | BDP | 151 | 217 | 2 | 0 | 2 | – |
| Intravenous | B-17-MP | 6185 | – | 100 | – | – | – |
| Oral | B-17-MP | 2540 | 58 | 41 | 41 | – | – |
| Intranasal | B-17-MP | 2723 | 67 | 44 | 43 | – | < 1 |
| Inhaled | B-17-MP | 3851 | 2383 | 62 | 26 | 36 | – |
| Intravenous | Total BOH | 10138 | – | 100 | – | – | – |
| Oral | Total BOH | 2132 | 49 | 21 | 21 | – | – |
| Intranasal | Total BOH | 2287 | 56 | 23 | 22 | < 1 | |
| Inhaled | Total BOH | 3343 | 2158 | 33 | 13 | 20 | |
1
Total BOH is the sum of the measured BDP, B-17-MP and BOH AUC values expressed as BOH equivalents.
2
Values corrected for charcoal block efficiency.